Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MAXOMAT ®, biosynthetic growth hormone
MAXOMAT, biosynthetic growth hormone · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MAXOMAT ®, biosynthetic growth hormone | DRUG | 2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration |
Inclusion Criteria: * Children and adolescents with Noonan's syndrome with a height \< -2 SD and no progressive cardiopathy Exclusion Criteria: * Age \< 3 years * Height ≥ -2 SD The above information is not intended to contain all considerations relevant to a patient's potential participation in...
MAXOMAT is a biosynthetic growth hormone studied for treating short stature in children with Noonan Syndrome, a rare genetic condition. It was evaluated in a Phase 3 trial of 36 children aged 3 years and older in France to assess its effect on growth.
MAXOMAT is developed by Sanofi, which trades on the New York Stock Exchange under the ticker SNY. Sanofi is the sponsor of the clinical program evaluating the biosynthetic growth hormone in pediatric Noonan Syndrome.
MAXOMAT has been studied in a Phase 3 clinical trial in Noonan Syndrome. The trial, NCT00452725, is listed as completed. MAXOMAT is an investigational biosynthetic growth hormone and is not described as approved for this indication.
MAXOMAT has been evaluated in one clinical trial, NCT00452725, titled Effect of MAXOMAT on the Growth of Small Children to NOONAN's Syndrome. The Phase 3 study enrolled 36 participants in France, included both sexes, and had a minimum age of 3 years. It is completed.
Yes. MAXOMAT is also written as MAXOMAT and referred to as biosynthetic growth hormone, so searches using either name point to the same product developed by Sanofi for Noonan Syndrome.
The Phase 3 trial NCT00452725 was an uncontrolled study, not randomized and not double blind, enrolling 36 children with Noonan Syndrome in France. Participants were 3 years of age or older, and the study is completed.